Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.79), $0.45 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.79 million.

GUIDANCE:

The company expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• New Zealand Energy Corp. swings to profit in Q2 2026
• UBS Reiterates Buy Rating on Cheniere Energy (LNG)